Adaptive Biotechnologies

Adaptive will work with NCI's Cancer Therapy Evaluation Program to use its ImmunoSeq platform for biomarker discovery in clinical trials. 

The companies will evaluate Adaptive's ClonoSeq assay for monitoring minimal residual disease in multiple myeloma patients treated with Janssen's Darzalex.

The researchers plan to profile patients with both Adaptive Biotechnologies' ImmunoSeq platform and 10x Genomics' single-cell immune repertoire profiling technology. 

Analyses of T cell therapy-responsive metastatic HPV-positive cervical cancers suggest the immune cells largely respond to tumor rather than viral antigens.

Adaptive aims to commercialize and scale its techniques to identify immune signatures in other infectious diseases, autoimmune disorders, and even cancer.

The companies plan to codevelop Adaptive's ClonoSeq assay to measure minimal residual disease in ALL. 

The partners will characterize patient immune response to two new investigational immunotherapies from Argos Therapeutics.

The company is using its MIRA assay internally and in research collaborations to identify biomarkers that can serve as the basis for immunotherapies. 

Executives from Thermo Fisher Scientific, Qiagen, Danaher, Counsyl, Human Longevity, and Adaptive Biotechnologies provided business updates to conference goers.

An NGS-based assay was better at diagnosing CTCL than PCR-based tests, and could distinguish between malignant and benign skin lesions and identify recurrence.

Pages

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.